Main text {#Sec1}
=========

We read with great interest the work by Jayson et al. in *Lancet* (Oct. 2014). The authors presented a comprehensive review of outstanding quality. They remarked that mucinous ovarian carcinoma has a nearly 100% human V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (*Kras*) mutation as well as a high frequency of human epidermal growth factor receptor 2 (*Her2*) amplification \[[@CR1]\]. However, we respectfully disagree with Jayson et al.'s opinion.

Literature reviews revealed that in mucinous ovarian carcinoma, the frequency of *Her2* amplification/over-expression is estimated to be between 18 and 35% \[[@CR2]\], and the presence of human *Kras* mutations is 13 to 60% \[[@CR3]--[@CR5]\]. This preliminary report aims to enlighten the readership that the \~100% *Kras* mutant frequency and the high *Her2* amplification rate in mucinous ovarian carcinoma may be higher than what has been observed in other studies, including our own.

Briefly, genomic DNA was extracted from formalin-fixed, paraffin-embedded tissue blocks of 21 cases of mucinous ovarian carcinoma. All the donors' identities have been permanently deleted. Abbott PathVysion *Her2* DNA Probe Kit and the 2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) breast cancer scoring methods were used to examine for *Her2* FISH ratio. The *Kras* mutant-enriched polymerase chain reaction (PCR) Kits (FemtoPath®) and a following direct sequencing method were applied to analyze exon 2 of the *Kras* gene. The reason why we choose *Kras* exon 2 to analyze is because *Kras* gene mutations are mainly known to cluster in several hotspots, with exon 2 (codons 12 and 13) being most commonly affected \[[@CR6]--[@CR9]\].

The prevalence of *Kras* mutations and *Her2* amplification within 21 Taiwanese mucinous ovarian carcinoma cases is shown in Table [1](#Tab1){ref-type="table"}, which indicates that the amplification rate of *Her2* was 33.33% (*n* = 7), while the mutation rate of *Kras* was 61.90% (*n* = 13). Additionally, the rates of co-existing *Kras* mutations and *Her2* amplification were 9.52% (*n* = 2) (Table [1](#Tab1){ref-type="table"}). However, there was a lack of statistically significant association between *Her2* amplification and *Kras* mutations (*p* = 0.057).Table 1The prevalence and relationship of *Kras* mutations and *Her2* amplification in mucinous ovarian carcinoma*Her2* non-amplification*Her2* amplificationTotal*n* (%)*n* (%)*n* (%)*Kras* wild type3 (14.29)5 (23.81)8 (38.10)*Kras* mutation11 (52.38)2 (9.52)13 (61.90)Total14 (66.67)7 (33.33)21 (100.00)*P* value0.056^a^*n (%)* number (percentage)^a^Fisher's exact test

Of the 13 cases of mucinous ovarian carcinoma with *Kras* mutations, 12 cases had a single missense mutation, which was composed of G12V in 4 cases, G12D in 5 cases, G12A in 1 case and A11V in 2 cases. The remaining 1 case had triple missense mutations---A11V, G13N and V14I. Moreover, both A11V and V14I were novel discoveries, based on the Catalogue of Somatic Mutations in Cancer (COSMIC) database \[[@CR10]\].

Conclusion {#Sec2}
==========

Both *Her2* amplification and *Kras* activating mutations are not mutually exclusive, which indicates that *Her2*/*Kras*/mitogen-activated protein kinases (MAPK) is a crucial pathway in the carcinogenesis of mucinous ovarian neoplasms. Targeting this pathway seems to be a viable therapeutic option for patients with recurrent or advanced stage mucinous ovarian carcinoma. Treatment selection based on the molecular alterations of *Her2* and *Kras* can possibly produce superior therapeutic effects compared with nonselective treatments. Additionally, functional impacts of these 2 novel *Kras* mutations (A11V, V14I) are still unknown; further studies using bioinformatics tools and molecular modeling are encouraged.
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